Black Diamond Therapeutics (BDTX)
(Real Time Quote from BATS)
$5.82 USD
+0.07 (1.22%)
Updated Jul 22, 2024 03:24 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BDTX 5.82 +0.07(1.22%)
Will BDTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDTX
Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?
Black Diamond (BDTX) is on the Move, Here's Why the Trend Could be Sustainable
BDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect?
Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know
Other News for BDTX
Black Diamond Therapeutics management to meet with Piper Sandler
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Black Diamond Therapeutics (BDTX) and Biogen (BIIB)
Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive
12 Health Care Stocks Moving In Tuesday's Intraday Session
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Black Diamond Therapeutics (BDTX)